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BRIEF DEFINITIVE REPORT
 The detection of high frequencies of HIV-1 –
 specifi c CD4 and CD8 T cells in HIV-1 – in-
fected subjects with nonprogressive disease ( 1 ), 
the demonstration that CD8 T cells are key play-
ers in vivo in the control of SIV replication ( 2 ), 
and the association of polyfunctional CD4 and 
CD8 T cells with better control of virus replica-
tion ( 1, 3, 4 ) provided the rationale for develop-
ing T cell vaccine strategies that, although they 
are unlikely to prevent infection, may eventually 
control HIV replication after infection ( 5 ). 
 The T cell vaccines that have entered clini-
cal evaluation include adenovirus (Ad) and 
poxvirus vectors ( 6, 7 ). Ad vectors were used 
either alone or in combination with DNA-
based vaccines. Each of these approaches has 
induced vigorous T cell responses ( 8, 9 ) and 
has partially controlled SIV replication in non-
human primates ( 6 ). The high seroprevalence 
to some Ad serotypes in target populations re-
mains a major issue for these vectors ( 7, 8 ). 
 On the basis of the encouraging preclini-
cal and phase I/II clinical programs, a trivalent 
Ad5-gag/pol/nef vaccine candidate entered a 
phase II test-of-concept-effi  cacy study called 
STEP in December 2004 and enrolled 3,000 
high-risk HIV seronegative subjects. The pri-
mary objectives of the study were to determine 
the eff ects of the vaccine on the reduction of 
the acquisition of infection and on the reduc-
tion of the set-point viremia. Late last year, 
STEP was prematurely terminated because of a 
lack of effi  cacy and because of the observation 
of a twofold increase in the incidence of HIV 
acquisition among vaccinated recipients with 
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 The STEP HIV vaccine trial, which evaluated a replication-defective adenovirus type 5 (Ad5) 
vector vaccine, was recently stopped. The reasons for this included lack of effi cacy of the 
vaccine and a twofold increase in the incidence of HIV acquisition among vaccinated re-
cipients with increased Ad5-neutralizing antibody titers compared with placebo recipients. 
To model the events that might be occurring in vivo, the effect on dendritic cells (DCs) of 
Ad5 vector alone or treated with neutralizing antiserum (Ad5 immune complexes [IC]) was 
compared. Ad5 IC induced more notable DC maturation, as indicated by increased CD86 
expression, decreased endocytosis, and production of tumor necrosis factor and type I 
interferons. We found that DC stimulation by Ad5 IC was mediated by the Fc  receptor IIa 
and Toll-like receptor 9 interactions. DCs treated with Ad5 IC also induced signifi cantly 
higher stimulation of Ad5-specifi c CD8 T cells equipped with cytolytic machinery. In con-
trast to Ad5 vectors alone, Ad5 IC caused signifi cantly enhanced HIV infection in DC – T cell 
cocultures. The present results indicate that Ad5 IC activates a DC – T cell axis that, to-
gether with the possible persistence of the Ad5 vaccine in seropositive individuals, may set 
up a permissive environment for HIV-1 infection, which could account for the increased 
acquisition of HIV-1 infection among Ad5 seropositive vaccine recipients. 
© 2008 Perreau et al. This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the fi rst six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons
.org/licenses/by-nc-sa/3.0/).
2718 ACTIVATION OF A DENDRITIC CELL – T CELL AXIS BY AD5 IMMUNE COMPLEX | Perreau et al. 
In particular, we investigated the eff ects of Ad5 immune 
complex (IC) exposure on DCs, Ad5-specifi c CD4 and CD8 
T cell responses, and enhancement of HIV infection. 
 RESULTS AND DISCUSSION 
 Effects of Ad5 IC on DCs 
 Ad5-specifi c memory T cells and Ad5 NAbs are an impor-
tant component of Ad5 preexisting immunity ( 11 ), and inter-
action between Ad5 vector and NAbs certainly occurs rapidly 
after the administration of vectors in vivo. Ad5 IC are also 
well characterized in vitro ( 12, 13 ). Thus, we investigated the 
eff ects of Ad5 IC on DCs. For these purposes, we generated 
Ad5 IC by mixing Ad5 vectors with sera containing Ad5 
NAbs. Formation of ICs was determined by assessing C1q 
(complement protein 1q) binding ( 14 ). To reproduce the 
scenario in the STEP trial, the Ad5 vectors used in the pres-
ent study are also E1/E3 deleted. To preclude the possibil-
ity that the eff ects were caused by complement activity, 
high Ad5 neutralizing antibodies (Abs [NAbs]) titers com-
pared with placebo recipients (www.HVTN.org). 
 Several hypotheses have been proposed to explain the in-
creased acquisition of HIV infection including the following: 
unique microenvironment of the mucosal compartment where 
the mechanisms for increased acquisition to HIV infection 
likely operate; generation of enhancing Abs that facilitate HIV 
infection; and vector-mediated activation of Ad5-specifi c CD4 
T cells that become ideal targets for HIV infection. It is impor-
tant to mention that Ads are not cleared after infection, and 
numerous clinical reports have demonstrated that Ads cause 
latent infections that are normally well controlled by the host 
( 10 ). Therefore, the administration of an Ad5 vector, its persis-
tence, and continual exposure may have an impact on both 
Ad-specifi c Abs generation and T cell responses. 
 In this study, we developed a series of ex vivo strategies to 
delineate the immunological events that may have operated 
among vaccine recipients with preexisting immunity to Ad5. 
 Figure 1.  DCs activation and maturation.  (a) Flow cytometry analysis of CD86 expression after treatment of DCs with Ad5 vector alone (fi lled 
square), Ad5 IC (formed with a fi xed Ad5 dose and increasing serum volumes [Ad5 NAb titer of 512]; fi lled diamonds), neutralizing serum (NS) alone (open 
triangles) and mock-treated DCs (open circle). (b) Untreated DCs (open circle) treated with a range of Ad5 doses (fi lled squares) or with Ad5 IC (fi lled dia-
monds) formed with 20  μ l of sera (Ad5 NS titer of 512) and various Ad5 doses and with NS alone (open triangle). (c) Flow cytometry profi le of CD40 and 
CD86 expression in DCs treated with Ad5 vector, Ad5 vector plus NNS, or Ad5 IC. (d) Cumulative data (fi ve DC donors and eight different sera) of CD86 
expression. (e) Ag uptake after incubation of DCs with Ad5 vector, Ad5 IC, LPS, or mock treated. The assays were repeated three times with similar results. 
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of TNF-  and IFN-I from DCs were observed either at a 
fi xed dose of Ad5 vector together with increasing volume 
of serum or vice versa ( Fig. 2, a and b ). No secretion of the 
other investigated cytokines was observed (unpublished data). 
We then investigated the relationship between the NAb titers 
and the levels of cytokines secretion. Interestingly, we found 
a signifi cant correlation (P  < 0.05) between the levels of 
TNF-  and IFN-I secreted and the Ad5 NAb titers ( Fig. 2, 
c and d ). Collectively, these results indicate that Ad5 IC in-
duced greater activation and maturation of DCs and, more 
importantly, the anti-Ad5 NAb titer was a key determinant 
in the induction of DCs activation. 
 Ad5 IC signal through the Fc  receptors (Fc  Rs) 
 According to previous studies, cross-linking of the Fc  Rs by 
immobilized Igs induces expression of costimulatory mole-
cules ( 18 ). To better defi ne the role of Fc  Rs, DCs were 
treated with Ad5 IC and the induction of TNF-  and IFN-I 
secretion was determined in the presence or absence of block-
ing Abs against Fc  RI, IIa, and III. The three Fc  Rs were 
diff erently expressed on DCs with the Fc  RIIa the most ex-
pressed (Fig. S2, available at http://www.jem.org/cgi/content/
full/jem.20081786/DC1). We found that blocking Fc  RI, 
III, and particularly IIa reduced the secretion of TNF-  and 
IFN-I ( Fig. 3 a ). These data demonstrate that Fc  Rs are 
heat-inactivated sera (30 min at 56 ° C) were used throughout 
this study. The eff ects of Ad5 IC on DCs were assessed initially 
by analyzing the induction of the expression of costimulatory 
molecules (CD40 and CD86). Consistent with previous 
studies ( 15 ), Ad5 vectors alone did not induce a substantial 
increase in the expression of costimulatory molecules by 
immature DCs ( Fig. 1, a – c ). The dose of Ad5 vector used, 
2.5  × 10 4 physical particles (pp)/cell was consistent with that 
used in previous studies ( 11, 16 ). To determine the eff ects of 
Ad5 IC, ICs were generated by progressively increasing the 
volume of serum that contained high Ad5 NAbs titers ( ~ 512) 
in the presence of a fi xed dose of Ad5 vector. The neutraliz-
ing activity of the sera was confi rmed by determining the 
levels of Ad5 vector transduction as previously described ( 14 ) 
and using DCs. The percent of AdGFP-transduced DCs was 
inversely proportional to the volume of serum, thus demon-
strating the presence of Ad5 NAbs (Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20081786/DC1). 
 Up-regulation of CD86 expression was observed 48 h af-
ter treatment of immature DCs with Ad5 IC, and the up-
regulation paralleled the increase in serum volume and thus 
in Ad5 IC formation ( Fig. 1 a ). Similarly, up-regulation of 
CD86 was also observed using a fi xed volume of serum and 
increasing the amount of Ad5 vector ( Fig. 1 b ). No signifi -
cant increase in the expression of CD86 was observed in the 
presence of serum or with Ad5 vector alone ( Fig. 1, a – d ). 
Signifi cantly (P  < 0.05), increased expression of CD40 and 
CD86 were observed in the presence of Ad5 IC and not in 
the presence of Ad5 vector alone or after treatment of DCs 
with Ad5 plus a nonneutralizing serum ( Fig. 1, c and d ). 
 To test the functional maturation of DCs induced by Ad5 
IC, we assayed their ability to take up antigens (Ags). Imma-
ture DCs effi  ciently capture Ags primarily through macro-
pinocytosis and mannose receptor-mediated endocytosis, but 
they lose this function during maturation ( 17 ). Immature DCs 
and DCs treated with Ad5 vector alone, with Ad5 IC, or with 
LPS were incubated with FITC-labeled dextran, and the level 
of Ag uptake was evaluated as a function of time ( Fig. 1 e ). 
Consistent with functional immaturity, mock-treated imma-
ture DCs maintained their ability to internalize the dextran. 
DCs incubated with Ad5 vector alone induced modest DC 
maturation and, indeed, their ability to Ag uptake was par-
tially preserved. Consistent with the induction of maturation, 
Ag uptake by DCs treated with Ad5 IC or LPS was lost. 
 To better defi ne the eff ects of Ad5 IC on activation and 
maturation of DCs, we determined the cytokine profi le of 
DCs treated with Ad5 vector, sera  ± NAbs, Ad5 incubated 
with a nonneutralizing serum (NNS) or Ad5 IC. The panel 
of cytokines investigated included TNF-  , IL-12p70, IL-10, 
IFN-I, IFN-  , and IL-1  . DCs treated with Ad5 vector, 
Ad5/NNS, or neutralizing serum, did not induce the release 
of any signifi cant levels of the cytokines tested ( Fig. 2, a and b ; 
and not depicted). In contrast, when assaying Ad5 IC our re-
sults were consistent with those found when testing the 
eff ects of Ad5 IC on the induction of the expression of costimu-
latory molecules ( Fig. 1 ). Progressive increments in secretion 
 Figure 2.  Secretion of proinfl ammatory cytokines from DCs. 
(a) DCs were treated with Ad5 IC (TNF-  , fi lled diamonds; IFN-I, open 
diamonds) formed with a fi xed dose of Ad5 vector and a range of serum 
volumes (Ad5 NS titer was 512), NS alone (TNF-  , fi lled triangles; IFN-I, 
open triangles). Culture supernatants were collected and analyzed for the 
presence of TNF-  by ELISA and IFN-I. (b) DCs were also treated with Ad5 
vector alone (TNF-  and IFN-I, fi lled and open squares, respectively) or 
with Ad5 IC (TNF-  and IFN-I, fi lled and open diamonds, respectively) 
formed with 20  μ l of serum (Ad5 NAb titer was 512) and untreated DCs 
(IFN-I and TNF-  , open and fi lled circles, respectively). Representative 
data of one out of nine subjects are shown. (c and d) Correlation between 
levels of TNF-  and IFN-I secretion and Ad5 NAb titers. Each point on the 
line results from the mean value of several pooled sera analyzed. At least 
28 sera were analyzed for TNF-  or IFN-I in duplicate. Statistical analysis 
was performed using Spearman ’ s rank correlation. 
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stream events of receptor-mediated Ad5 IC internalization 
were involved in the delivery of activation signals. 
 Internalized Ad5 IC deliver activation signals 
 On the basis of the observations detailed in the previous sec-
tion, it is possible that Fc  R-mediated Ad5 IC internalization 
preferentially delivers some Ad components (proteins, virus-
associated RNA, or the double-stranded DNA genome) to 
distinct subcellular compartments. To test this hypothesis, we 
incubated DCs with a helper-dependent Ad5 vector alone 
or complexed with sera containing NAbs (helper-dependent 
[HD] IC). Although the genomes of helper-dependent vectors 
are deleted in all viral genes, the virions contain the same core 
and capsid proteins and virus-associated RNAs ( 19 ). We found 
that neither the helper-dependent vector alone nor the HD IC 
promoted the release of TNF-  or IFN-I ( Fig. 3 b ), suggesting 
that the genome of the E1/E3-deleted Ad5 vector harbors 
critical signals for complete DC activation and maturation. 
 In this regard, nucleic acids of viral or mammalian origin 
can be recognized by intracellular pathogen recognition re-
ceptors. For example, human lupus Ab – DNA complexes ac-
tivate DCs through the interaction between Fc  RII and 
TLR9 ( 20 ). Furthermore, several potential immunoregula-
tory sequences (IRSs) can inhibit the release of IFN-I after 
stimulation with TLR9 and TLR7 agonists ( 21 ). Among 
these, IRS 869 mediated the most potent inhibition of IFN-I 
secretion in TLR9-stimulated plasmacytoid DC ( 21 ). We 
therefore asked whether IRS 869 could suppress TNF-  
and/or IFN-I production induced by Ad5 IC. We found that 
IRS 869 suppressed both TNF-  and IFN-I production after 
stimulation with Ad5 IC ( > 90% inhibition;  Fig. 3 c ). LPS, 
which stimulates DCs through the cooperation of CD14 with 
TLR4 ( 22 ), and CpG (TLR9 agonist) ( 21 ) were used as con-
trols. IRS 869 did not inhibit TNF-  or IFN-I production 
by DCs stimulated with LPS, whereas it inhibited cytokine 
production of DCs stimulated with CpG ( Fig. 3 c ). 
 Consistent with previous studies ( 23, 24 ), our data sug-
gest that Ad5 IC are internalized via Fc  RIIa and are likely 
delivered to intracellular compartments where the vector ge-
nome interacts with TLR9, which in turn leads to activation 
of DCs. Importantly, these data argue against a major role for 
Ad capsid proteins and RNA. 
 Ad5 IC stimulate/activate Ad5-specifi c CD4 and CD8 T cells 
 To investigate the eff ects of Ad5 IC on the stimulation/acti-
vation of Ad5-specifi c CD4 and CD8 T cells in Ad5 sero-
positive subjects, we developed an ex vivo stimulation assay 
of Ad5-specifc T cells that may mimic those operating in 
vivo. DCs were generated from five subjects with high 
( > 1,000) Ad5 NAb titers. Immature DCs were incubated 
with Ad5 vector alone or with Ad5 IC for 24 h. Two sera 
were used to generate Ad5 ICs for each DC population, auto-
logous serum (from the donor-providing DCs) and heterolo-
gous serum with high (4,096) Ad5 NAb titer. At the end of 
the incubation period, Ad5 vector or Ad5 IC – treated DCs 
were used to stimulate Ad5-specifi c CD4 and CD8 T cells 
involved in delivering an Ad5 IC – derived activation signal to 
DCs. To further exclude the eff ects of unknown serum com-
ponents, we used purifi ed Igs ( 14 ) to generate Ad5 IC and 
confi rmed the effi  cient induction of DC activation (unpub-
lished data). The purifi ed Igs were predominantly IgG (IgM 
and IgA were a minor fraction), and IgG 1 and IgG 2 were the 
predominant isotypes (unpublished data). 
 Signaling through Fc  Rs may be caused by either direct 
cross-linking or by downstream events of receptor-mediated 
internalization. To discriminate between these two possibili-
ties, DCs were cultured in wells coated with purifi ed Ad5-
specifi c Abs. No signifi cant secretion of TNF-  , IL-12p70, 
IL-10, IFN-I, IFN-  , or IL-1  was observed (unpublished 
data), thus suggesting that cross-linking of Fc  Rs is not an 
activation signal suffi  cient to induce the release of cytokines 
in DCs despite the fact that it induces expression of costimu-
latory molecules. Therefore, these results suggested that down-
 Figure 3.  Ad5 IC deliver the activation signal to DCs through 
Fc  Rs and TLR9. (a) DCs were treated with Ad5 IC in the presence of 
anti-Fc  RI, IIa, and III blocking Abs. Culture supernatants were analyzed 
for the secretion of TNF-  and IFN-I. Results are expressed as the percent 
of the TNF-  or IFN-I secretion levels in the cultures stimulated with Ad5 
IC in the presence or absence of Fc  Rs blocking Abs. (b) DCs were treated 
with Ad5 vector, helper-dependent vector, Ad5 IC, or HD IC . Supernatants 
were analyzed for the presence of TNF-  and IFN-I. Results are expressed 
as the percent of the TNF-  and IFN-I secretion levels versus controls 
(treatment of DCs with Ad5 IC). (c) DCs were stimulated with Ad5 IC (NAb 
titer of 512) and LPS (TLR4 agonist) or CpG in the presence or absence of 
TLR9 inhibitor. At the end of the stimulation period, supernatants were 
analyzed for the presence of TNF-  and IFN-I. Results are expressed as 
the percent of the cytokine levels measured in culture treated with TLR9 
inhibitor versus those found in control cultures (absence of inhibitors). All 
of the experiments in  Fig. 3 were performed twice in triplicate. Error bars 
represent SEM. 
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 Figure 4.  Ad5 vector and Ad5 IC stimulate Ad5-specifi c CD4 and CD8 T cells.  (a) Cumulative data on the percentage of the total cytokine re-
sponse (IL-2 + TNF-  + IFN-  ) of Ad5-specifi c CD4 and CD8 T cells after stimulation with Ad5 vector or Ad5 IC – treated DCs. The data were generated 
from fi ve Ad5 seropositive subjects with Ad5 Ab titers  > 1,000. Blood mononuclear cells were stimulated with DCs treated with either autologous or 
heterologous neutralizing sera. (b) Flow cytometry profi les of CD8 T cells secreting IL-2, TNF-  , and IFN-  after stimulation with Ad5 vector, Ad5 + NNS, 
or Ad5 IC – treated DCs from a representative subject. All the possible combinations of the responses are shown on the x axis, and the functionally distinct 
cell populations within the responding CD8 T cell populations are shown on the y axis. Responses are grouped and color-coded on the basis of the num-
ber of functions. In the pie chart, each slice corresponds to the fraction of CD8 T cells with a given number of functions within the responding CD8 T cell 
populations. Bars correspond to the fractions of functionally distinct T cell populations within the total CD8 T cells. (c) Perforin and granzyme B expres-
sion in proliferating CD8 T cells. Analysis of perforin and granzyme B expression was determined on gated CFSE-low proliferating CD3 + CD8 + T cells after 
stimulation with DCs treated with Ad5 or Ad5 IC. Cumulative data are also shown. 
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assessed by measuring p24 in the culture supernatants. It is 
important to mention that DCs, through the formation of 
conjugates with CD4 T cells, facilitate productive HIV-1 in-
fection in cell cultures even in the absence of polyclonal or 
Ag-specifi c activation of T cells ( 25 ). Indeed, we observed 
productive HIV-1 infection in cell cultures containing mock-
treated DCs mixed with autologous blood mononuclear cells 
( Fig. 5 ). Nonetheless, we consistently observed approximately 
threefold higher levels of HIV replication in the cell cultures 
containing blood mononuclear cells stimulated with DCs 
treated with Ad5 IC as compared with Ad5 vector or cul-
tured with DCs alone ( Fig. 5 ). The mean p24 level at day 4 
was 3,230 pg/ml in the culture of blood mononuclear cells 
stimulated with DCs treated with Ad5 vector alone versus 
10,800 pg/ml in the culture of blood mononuclear cells stim-
ulated with DCs treated with Ad5 IC (P  < 0.05). At day 7, 
the mean p24 level was 64,400 pg/ml in the culture of blood 
mononuclear cells stimulated with DCs treated with Ad5 
vector alone versus 207,600 pg/ml in the culture of blood 
mononuclear cells stimulated with DCs treated with Ad5 IC 
(P  < 0.001). Therefore, Ad5 IC likely induced greater activa-
tion of T cells that translated into enhanced levels of HIV 
replication in tissue culture. 
 Our study advances our understanding of the likely im-
munological events operating after Ad5 vector-based vacci-
nation and suggests a series of events that could explain the 
increase in acquisition of HIV infection in Ad5 seropositive 
subjects in the STEP trial. During Ad5 vector – mediated gene 
transfer, the vectors likely infect several target cells, including 
professional Ag-presenting cells like DCs. Infection of these 
latter cells will eventually activate memory Ad5-specifi c CD4 
and CD8 T cells and hopefully generate an HIV-specifi c 
T cell response. However, the presence of high Ad5 NAbs 
titers is associated with the formation of Ad5 IC. Compared 
with Ad5 vector alone, Ad5 IC induced  “ hyperactivation ” 
and maturation of DCs, as indicated by the increased expres-
sion of costimulatory molecules, the loss of the capacity of Ag 
uptake, and the secretion of TNF-  and IFN-I. The activation 
 Figure 5.  Ad5 IC stimulates HIV infection in vitro. Mean p24 levels 
at day 0, 4, and 7 in blood mononuclear cells from donors were cultured 
with Ad5 or Ad5 IC – treated autologous DCs. Uninfected cultures and HIV 
infection in cultures in which blood mononuclear cells were mixed with 
untreated DCs were used as controls. Four donors were studied. Data 
represent the mean of triplicate determinations. 
from autologous blood mononuclear cells. We then assessed 
secretion of IL-2, IFN-  , and TNF-  (6 h after stimulation) 
using polychromatic fl ow cytometry. No signifi cant diff er-
ence (P  > 0.05) was observed in the percent of total, IL-2, 
IFN-  , and TNF-  – secreting Ad5-specifi c CD4 T cells in 
blood cells stimulated with Ad5 vector – or Ad5 IC – treated 
DCs ( Fig. 4 a ). In contrast, a highly signifi cant (P  < 0.001) 
approximately threefold diff erence was found in the percentage 
of total cytokine-secreting Ad5-specifi c CD8 T cells stimu-
lated with Ad5 IC – treated DCs compared with Ad5 vector –
 treated DCs ( Fig. 4 a ). Furthermore, major changes in the 
cytokine profi le of Ad5-specifi c CD8 ( Fig. 4 b ), but not 
CD4, T cells (Fig. S3, available at http://www.jem.org/cgi/
content/full/jem.20081786/DC1) were observed between the 
two stimulation conditions. In particular, we detected a sig-
nifi cant (P  < 0.05) increase in the dual IFN-  + /TNF-  + 
( Fig. 4 b ) and a signifi cant (P  < 0.05) decrease in the IL-2 –
 secreting (IL-2 + /IFN-  + /TNF-  + IL-2 + /TNF-  + and single 
IL-2 + ;  Fig. 4 b ) CD8 T cell populations. With regard to Ad5-
specifi c CD4 T cells, the cytokine profi le was modestly dif-
ferent between Ad5 vector alone and Ad5 IC – treated DCs 
These results indicate that Ad5 IC induced stimulation of 
higher frequencies of Ad5-specifi c memory CD8 T cells with 
an eff ector cytokine profi le. 
 We next determined the eff ects of Ad5 IC on the prolif-
eration capacity of Ad5-specifi c memory T cells and consis-
tently observed a trend toward increase proliferation (about 
twofold) of CD4 and CD8 T cells stimulated with Ad5 IC –
 treated DCs, although these diff erences did not reach statisti-
cal significance (P  > 0.05; Fig. S4, available at http://www
.jem.org/cgi/content/full/jem.20081786/DC1). We also 
determined the cytotoxic profi le of the proliferating (CFSE 
low) Ad5-specifi c CD8 T cells based on the expression of 
perforin and granzyme B. The proportion of Ad5-specifi c 
CD8 T cells expressing perforin and granzyme B was   2.5-
fold greater (P  < 0.05) when Ad5 IC – treated DCs were used 
as stimuli ( Fig. 4 c ). 
 Collectively these results indicate that Ad5 IC induced 
substantial anti-Ad5 vector eff ector CD8 T cells and a trend 
toward a larger expansion of Ad5-specifc T cells. The more 
eff ective stimulation of Ad5-specifi c CD8 T cells likely 
results from the capacity of DCs to effi  ciently process and 
present exogenous Ags, such as IC, to CD8 T cells via cross-
presentation ( 24 ). 
 Ad5 IC enhances HIV infection 
 It was critical to investigate whether the increased T cell acti-
vation induced by Ad5 IC enhanced HIV infection. To ad-
dress this issue we used an ex vivo model that likely mimics 
the cellular interactions that occurred during the STEP trial. 
We stimulated DCs with Ad5 vector or Ad5 IC and then in-
cubated these cells with autologous blood mononuclear cells 
from four subjects to reactivate memory Ad5-specifi c T cells. 
Autologous or heterologous (4,096 titer) NS sera were used 
to generate Ad5 IC. The cocultures were then incubated 
with HIV-1 LAV . Ex vivo HIV infection and propagation was 
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 NAb titers.  The neutralizing activity of a panel of sera ( n = 76) was deter-
mined by transduction inhibition assays ( 14 ) using the 911 cell line. With re-
gard to the DC transduction assay, immature DCs (2.5  × 10 5 cells) were 
resuspended in medium containing 2.5  × 10 4 pp/cell and 0.016 – 20  μ l of se-
rum, incubated for 48 h, and then analyzed by fl ow cytometry. 
 Cytokine secretion.  DCs from 14 donors were incubated with AdGFP, 
Ad5 IC, or 50 ng/ml LPS ( Escherichia  coli 0127 B5; Sigma-Aldrich) for 48 h. 
Supernatants were collected and analyzed for the presence of TNF-  , IL-
12p70, IL-1  , IFN-  , and IL-10 by ELISA (BD). IFN-I quantifi cation was 
performed as previously described ( 15 ) using cells that contain a luciferase 
expression cassette under the control of IFN-I – inducible promoter. The NAb 
titers and number of sera analyzed for each titer were the following: 0, 1; 4, 
3; 8, 2; 16, 5; 32, 1; 64, 6; 128, 4; 512, 2; and titer 1,024, 4 sera. 
 Ag uptake.  Ag uptake was determined using FITC-labeled dextran (MW 
10,000; Sigma-Aldrich) as previously described ( 15 ). In brief, immature DCs 
were incubated with Ad  gal, Ad5 IC, or 50 ng/ml LPS for 48 h. DCs were 
then washed and incubated with 1 mg/ml FITC-labeled dextran for 10, 30, or 
90 min. Control DCs were incubated at 4 ° C. Assays were performed twice. 
 FcR Abs.  The following monoclonal Abs were used for functional assays: 
CD16 (Fc  RIII; 3G8; BD), CD32a (Fc  RIIa IV.3), CD32 (Fc  RII AT10), 
and CD64 (Fc  RI; 10.1) ( 20 ). 
 Expression of costimulatory molecules.  DCs were cultured either alone 
or with Ad  gal vector or Ad  gal mixed with 20  μ l of neutralizing serum and 
50 ng/ml LPS for 48 h. The expression of costimulatory molecules was as-
sessed on HLA-DR – positive cells using an HLA-DR Alexa Fluor 700 – con-
jugated Ab (LN3; eBioscience). Five DC donors and eight sera were used. 
 Intracellular cytokine staining.  DCs were fi rst treated for 24 h with Ad5 
vector alone or with Ad5 IC. Cell cultures were then extensively washed, 
mixed with autologous blood mononuclear cells (10 6 cells), and cultured for 
6 h in 1 ml of complete media containing 1  μ l/ml GolgiPlug (BD). Intracel-
lular cytokine staining was performed as previously described ( 30 ). The Abs 
used were the following: CD4-APC-H7, CD8-PerCP-Cy5.5, CD3-ECD, 
IFN-  – AF700, IL-2 – PE, and TNF-  – PE-CY7. Data were acquired on an 
LSRII three laser (488, 633, and 405 nm; BD) and analyzed using FlowJo 
and SPICE 4.1.5 software (M. Roederer, Vaccine Research Center, NIAID, 
Bethesda, MA). 
 Ex vivo proliferation assay.  DCs were fi rst treated for 24 h with Ad5 
vector alone or with Ad5 IC. Cell cultures were then extensively washed, 
mixed with autologous blood mononuclear cells, and cultured for 6 d. Blood 
mononuclear cells proliferation was assessed using CFSE (Invitrogen) as pre-
viously described ( 9, 30 ). Cells were stimulated with Ad5 IC formed with 
autologous NS and heterologous serum. Stimulation with 100 ng/ml  Staph-
ylococcus aureus enterotoxin B was used as a positive control. All sera tested 
had Ad5 NAb titers  > 1,000. The percent of proliferating CD4 + and CD8 + 
T cells, i.e., CFSE-low cells, was determined in the CD3 + cell population. 
The criteria for scoring as positive the proliferating cell cultures included 
both CFSE-low cells  > 1% after subtracting the percent of CFSE-low cells in 
unstimulated cell cultures and stimulation index  > 3. The stimulation index 
was calculated by the fold increase between stimulated versus unstimulated 
cell cultures. Expression of perforin and granzyme B expression on CFSE-
low proliferating CD8 T cells was performed using APC-conjugated anti-
perforin (BioLegend) and AF700-conjugated anti-granzyme B (BD). 
 HIV infection in vitro.  DCs were fi rst treated for 24 h with Ad5 vector 
alone or with Ad5 IC. Cell cultures were then extensively washed, mixed 
with autologous blood mononuclear cells, and cultured for 48 h. Cell cul-
tures of 10 6 cells were then inoculated with 30 pg HIV-1 LAV for 3 h. At the 
end of the incubation, cells were washed, replated at 10 6 cells per well, and 
HIV replication was assessed by measuring p24 in the culture supernatant. 
signal to DCs mediated by Ad5 IC results in part from the 
cooperation between Fc  Rs and TLR9. 
 The survival signals and clonal expansion of memory T cells 
mediated by IFN-I ( 26, 27 ) may explain the eff ect of Ad5 
IC on the increase of Ad5-specifc memory eff ector CD8 
T cells, likely through cross-priming and the trend toward 
larger expansions of both Ad5-specifi c memory CD4 and 
CD8 T cells. The reactivation of Ad5-specifi c memory T cells 
likely prevents eff ective generation of the primary immune re-
sponse against the vector-encoded HIV Ags through two 
nonexclusive mechanisms: one, an unfavorable cytokine en-
vironment resulting from the infl ammatory response caused 
by the Ad5 IC formation; and two, the killing of DCs. Be-
cause DCs will express not only HIV but also Ad5 Ags ( 28 ), 
they become a target of the reactivated Ad5-specifi c CD8 
T cells, thus resulting also in the reduction of the DC pool 
presenting HIV Ags. In support of this hypothesis, prelimi-
nary data from the STEP trial indicate that the percent of re-
sponders to HIV proteins (measured by IFN-  ELISpot) was 
less (  25%) in subjects with Ad5 NAb titers  > 200, and the 
magnitude of the HIV-specifi c T cell response (frequency of 
IFN-  – secreting cells in blood) was also reduced by   50% 
(www.HVTN.org). Finally, increased survival of activated 
memory Ad5-specifi c CD4 T cells mediated by IFN-I ( 26 ) 
may transiently enlarge this pool of memory CD4 T cells 
that eff ectively support HIV replication and spreading, thus 
facilitating susceptibility to HIV infection. Our results also 
provide new insights into the type of experimental strategies 
and assays that can be instrumental for the preclinical assess-
ment of the safety of other viral vector-based vaccines in ad-
dition to Ad5. 
 In conclusion, we have shown that ICs containing E1/
E3-deleted Ad5 vectors and NAbs cause a pattern of innate/
adaptive infl ammatory activation that, together with a possi-
ble persistence of the Ad5 vector, may provide the basis for a 
chronic permissive environment for HIV-1 infection, thus 
helping to explain the increased acquisition of HIV-1 infec-
tion among the Ad5 seropositive vaccine recipients in the 
STEP trial. Moreover, our results also suggest that the deliv-
ery/formulation of Ags through ICs may result in a powerful 
immunization strategy to stimulate T cells. 
 MATERIALS AND METHODS 
 Blood mononuclear cell and DC isolation.  Blood mononuclear cell 
isolation (from 14 healthy subjects) and monocyte-derived DC generation 
were performed as previously described ( 15 ). 
 Ad vectors.  Two E1/E3-deleted Ad5 vectors (Ad  gal and AdGFP) have 
been previously described ( 15 ). Ad  gal harbors a  lacZ expression cassette and 
was used in T cell stimulation, Ag uptake, Fc receptor blocking, in vitro 
HIV infection, and costimulatory molecule experiments. AdGFP harbors a 
GFP expression cassette and was used for the assessment of NAb titers, in 
DC transduction assays, and in costimulatory molecule experiments. The 
helper-dependent Ad5 vector ( 19 ) is deleted in all viral genes and contains a 
 lacZ expression cassette (provided by M. Castro, Gene Therapeutics Re-
search Institute, Cedars Sina Medical Center, University of California, Los 
Angeles, Los Angeles, CA). Ad5 vector titers were measured in virus pp/cell 
as described by Mittereder et al. ( 29 ). 
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Mock-infected cultures were used as a negative control. HIV infection 
was also determined in cultures in which blood mononuclear cells were 
mixed with untreated DCs. p24 measures were performed in triplicates 
and measurements were performed at days 0, 4 and 7 using an ELISA 
(Immunogenetics). 
 TLR inhibitors.  Phosphorothioate-protected IRS 869 and control oligo-
nucleotide (ODN; Sigma-Aldrich) were resuspended to make a fi nal con-
centration of 500  μ M. TLR9 immunostimulatory sequence 2216 was purchased 
from InvivoGen. In brief, 2.5  × 10 5 immature DCs were seeded in 500  μ l in 
48-well plates and treated with IRS 869 or control ODN (fi nal concentra-
tion of 5  μ M) for 2 h. Immunostimulatory sequence 2216 (also at 5  μ M) or 
Ad5 IC prepared using 20- μ l serum (NAbs titer  > 1,000) for 15 min at room 
temperature were then incubated with the DCs for   18 h at 37 ° C in 5% 
CO 2 . The supernatants were collected at the indicated times and tested for 
TNF-  or IFN-I. 
 Statistical analysis.  Statistical signifi cance (p-values) was calculated by us-
ing a Student ’ s  t test for the comparisons, a Spearman rank test for the corre-
lations, and a Wilcoxon rank test for the SPICE analyses. A two-tail p-value 
of  < 0.05 was considered signifi cant. The analyses of multiple comparisons 
have been taken into account for the calculation of statistical signifi cance. 
 Online supplemental material.  The four fi gures show data on Ad5 vec-
tor transduction effi  ciency, expression of diff erent Fc  Rs on DCs, and 
eff ects of Ad5 IC stimulation on CD4 T cells and T cell proliferation. 
Online supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20081786/DC1. 
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